research funding database


This opportunity is currently closed.

Sign up for Content alerts to stay informed when this or related funding opportunities are posted.

The Lawrence and Isabel Barnett Drug Development Program (ALS research worldwide)

Share this post

Text on a blue background says "Want to find funding & get support for grant-writing?" Logos of scientifyRESEARCH & GrantDesk appear below on a white background and an orange plus symbol appears between the two logos.
ERC webinar 2024

The Lawrence and Isabel Barnett Drug Development Program (2024) funded by the ALS Association offers funding for investigators in industry or academia worldwide focused on the preclinical assessment of therapeutics for amyotrophic lateral sclerosis (ALS).

The following drug discovery projects are of greatest interest:

  • In vivo efficacy testing of therapeutic candidates (pharmacological treatments, biological therapies, or gene therapy) in models of ALS.
  • Studies on pharmacokinetics, pharmacodynamics, preclinical toxicology/safety (ADME/Tox), dose-range finding, and target engagement.
  • Other IND enabling studies

This funding provides $500,000 USD total costs for two years, with indirect costs limited to 10%.

A letter of intent is due on December 18, 2023. Full applications are by invitation only and due on March 7, 2024.

The grant has closed Sign-up for our content alerts to be updated when it re-opens.

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

Sign-up for the
monthly funding newsletter

unsubscribe at any time